Johnson & Johnson (JNJ)
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
Johnson & Johnson's JNJ stock has risen 38.4% in the past six months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) for more than eight months since mid-June 2025 due to its positive earnings outlook and improving fundamentals.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Can J&J Sustain Its Double-Digit Oncology Growth Streak?
Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors. It is the #1 company in multiple myeloma, with key drug Darzalex being considered the foundational gold standard treatment.
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming.
Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility
Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.
Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory
The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.
J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push
Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing amid President Donald Trump's tariff threats.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different.
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues.
